Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs Tacrolimus With Excimer Laser in Localized Vitiligo
NCT07909668Enrolling by invitation
- Sponsor
- Kafrelsheikh University
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised, single-blind trial of ruxolitinib cream in Vitiligo (2 arms), sponsored by Kafrelsheikh University. Primary endpoint: Physician Global Assessment at 24 weeks. Started Jul 2026; status: enrolling by invitation.
02
Drugs
ruxolitinib cream
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07909668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909668.